Centers for Disease Control and Prevention (CDC) Advisory Committee Recommends Preferential Use Of Live Attenuated Influenza Vaccine (LAIV) For Eligible Children 2 To 8 Years Of Age
6/26/2014 8:58:33 AM
WILMINGTON, Del.--(BUSINESS WIRE)--The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions. The ACIP’s unanimous vote was based on a systematic evidence-based assessment methodology called the Grading of Recommendations Assessment, Development and Evaluation (also known as GRADE).
Help employers find you! Check out all the jobs and post your resume.
comments powered by